Insulet Co. (NASDAQ:PODD) has been given an average recommendation of “Buy” by the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $101.30.
A number of research analysts have recently issued reports on the company. BidaskClub cut Insulet from a “buy” rating to a “hold” rating in a research note on Thursday. Northland Securities reiterated a “buy” rating and set a $100.00 price target on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity upped their target price on shares of Insulet from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Tuesday, February 19th. Morgan Stanley dropped their target price on shares of Insulet from $105.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Finally, ValuEngine cut shares of Insulet from a “strong-buy” rating to a “buy” rating in a research report on Monday, January 7th.
In other Insulet news, Director John A. Fallon sold 5,000 shares of Insulet stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $100.00, for a total transaction of $500,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP David Colleran sold 4,826 shares of Insulet stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $80.00, for a total transaction of $386,080.00. The disclosure for this sale can be found here. Insiders have sold 91,964 shares of company stock worth $8,526,720 over the last ninety days. 3.60% of the stock is owned by insiders.
NASDAQ:PODD traded down $1.93 during midday trading on Monday, reaching $91.42. 39,181 shares of the stock traded hands, compared to its average volume of 645,944. Insulet has a 12-month low of $70.80 and a 12-month high of $108.90. The company has a quick ratio of 3.37, a current ratio of 3.99 and a debt-to-equity ratio of 2.79. The stock has a market capitalization of $5.57 billion, a price-to-earnings ratio of 1,828.40 and a beta of 1.59.
Insulet (NASDAQ:PODD) last released its quarterly earnings data on Monday, February 25th. The medical instruments supplier reported $0.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.10. The firm had revenue of $164.90 million for the quarter, compared to analyst estimates of $162.45 million. Insulet had a net margin of 0.58% and a return on equity of 1.73%. The business’s quarterly revenue was up 26.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.12) earnings per share. As a group, analysts expect that Insulet will post 0.23 EPS for the current year.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
See Also: Derivative
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.